retatrutide nonalcoholic fatty liver disease nash trial Analysis of Underscores Need for Targeted Treatment Mechanisms of NAFLD development and

These typically stabilized as dosing reached maintenance levels

Suspected side effects, including from unlicensed use, should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app

When dose reduction is appropriate Phase 3 trials include provisions for dose reduction: Gastrointestinal adverse events or inadequate oral intake may warrant stepping down to a lower dose level see Retatrutide Side Effects for incidence rates by dose BMI reaching 22 kg/m or below , or perceived excessive weight loss, allows dose reduction Treatment is discontinued at BMI 18.5 kg/m or below How Often and When to Take Retatrutide Injection frequency once weekly by subcutaneous injection, on the same day each week

Taking it during or right after a meal often improves comfort

After 12 hours, removing it is just as simple a little water or oil helps if it feels extra sticky